A patient centric commercial model for cancer care.
- Published in:
- Journal of Commercial Biotechnology, 2013, v. 19, n. 2, p. 40, doi. 10.5912/jcb601
- By:
- Publication type:
- Article
Works matching IS 14628732 AND DT 2013 AND VI 19 AND IP 2
Results: 12
1
2
Should the HHS decision to overrule FDA on Plan B be reversed?
- Published in:
- Journal of Commercial Biotechnology, 2013, v. 19, n. 2, p. 68, doi. 10.5912/jcb600
- By:
- Publication type:
- Article
3
Bowman v. Monsanto: Revisiting the Exhaustion Doctrine and its application to biotechnology and digital technologies.
- Published in:
- Journal of Commercial Biotechnology, 2013, v. 19, n. 2, p. 64, doi. 10.5912/jcb607
- By:
- Publication type:
- Article
4
Getting social with biotechnology business development.
- Published in:
- Journal of Commercial Biotechnology, 2013, v. 19, n. 2, p. 61, doi. 10.5912/jcb603
- By:
- Publication type:
- Article
5
Challenges and prospects for monoclonal antibodies in China.
- Published in:
- Journal of Commercial Biotechnology, 2013, v. 19, n. 2, p. 49, doi. 10.5912/jcb594
- By:
- Publication type:
- Article
6
A business perspective on IP: Open innovation vs. open source in commercializing biomedical opportunities.
- Published in:
- Journal of Commercial Biotechnology, 2013, v. 19, n. 2, p. 55, doi. 10.5912/jcb599
- By:
- Publication type:
- Article
7
Developing cell therapies: Enabling cost prediction by value systems modeling to manage developmental risk.
- Published in:
- Journal of Commercial Biotechnology, 2013, v. 19, n. 2, p. 27, doi. 10.5912/jcb585
- By:
- Publication type:
- Article
8
The financial ecosystem available to early-stage biotechnology firms and its misalignment with interests of these firms, of the biotechnology industry and with global disease burden.
- Published in:
- Journal of Commercial Biotechnology, 2013, v. 19, n. 2, p. 17, doi. 10.5912/jcb586
- By:
- Publication type:
- Article
9
Technology transfer: Bridging academic research and society -- a communicative approach.
- Published in:
- Journal of Commercial Biotechnology, 2013, v. 19, n. 2, p. 11, doi. 10.5912/jcb575
- By:
- Publication type:
- Article
10
Defining valuable information in a shifting industry.
- Published in:
- Journal of Commercial Biotechnology, 2013, v. 19, n. 2, p. 9, doi. 10.5912/jcb606
- By:
- Publication type:
- Article
11
Commercial Biotechnology in Mexico.
- Published in:
- Journal of Commercial Biotechnology, 2013, v. 19, n. 2, p. 6, doi. 10.5912/jcb605
- By:
- Publication type:
- Article
12
Pharmaceutical companies, faced with growing pricing pressures, should look outside their products for new revenue opportunities.
- Published in:
- Journal of Commercial Biotechnology, 2013, v. 19, n. 2, p. 3, doi. 10.5912/jcb.608
- By:
- Publication type:
- Article